Aerie Pharmaceuticals: Funding, Investors & Team (Aug 2026)
Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma. The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina. Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.
Aerie Pharmaceuticals has raised $88.0M across 1 funding round on record, the most recent a Post-IPO Equity of $88.0M announced in Dec 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aerie Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Dec 2021.
Aerie Pharmaceuticals Funding Rounds
Aerie Pharmaceuticals Founders and Leadership Team
Contact details for the Aerie Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Aerie Pharmaceuticals Funding Compared to Other Biotechnology Startups
Aerie Pharmaceuticals' latest round of $88.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aerie Pharmaceuticals in Biotechnology and Bedminster
Companies Similar to Aerie Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Aerie Pharmaceuticals Funding FAQs
What does Aerie Pharmaceuticals do?
Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma. The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina. Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.
How much funding has Aerie Pharmaceuticals raised?
Aerie Pharmaceuticals has raised $88.0M across 1 round on record. The most recent is a Post-IPO Equity of $88.0M announced in Dec 2021.
When did Aerie Pharmaceuticals last raise funding?
Aerie Pharmaceuticals' most recent funding round on record is a Post-IPO Equity of $88.0M, announced in Dec 2021.
Who is the CEO of Aerie Pharmaceuticals?
Raj Kannan is listed as CEO at Aerie Pharmaceuticals.
Where is Aerie Pharmaceuticals headquartered?
Aerie Pharmaceuticals is based in Bedminster, New Jersey, United States.
How many employees does Aerie Pharmaceuticals have?
Aerie Pharmaceuticals is in the 251-500 employee band.
How does Aerie Pharmaceuticals' funding compare to other Biotechnology startups?
Aerie Pharmaceuticals' latest round of $88.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Aerie Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aerie Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.